检索结果-南通市图书馆

Elucidation of Latent Risk of Navigation Using an Actual Ship Behavior Analysis

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Traffic and Transportation Engineering 2016年第3期4卷 131-140页

作者： Xinjia Gao Hidenari Makino masao furusho Graduate School of Maritime Sciences Kobe University Hyogo 658-0022 Japan Naval Architecture & Ocean Engineering Osaka University Osaka 565-0871 Japan

Historical Improvement of Legal Systems of Safety and Health for Mariners in Japan

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Historical Improvement of Legal Systems of Safety and Health...

Activation of hypoxia-inducible factor 1 attenuates periapical inflammation and bone loss

Asia Navigation Conference 2009

作者： Keiji SASAYA masao furusho Yoshiji YANO Toyama National College of Maritime Technology Graduate School of Maritime Sciences Kobe University 1-2 EbieNeriyaImizu city Toyama Prefecture

＜正＞*** Whether it is labor at sea or on land,the protection of the life,body,and health of workers is more important than anything *** number of Japanese mariners or seafarers working at sea in Japan is 74,618（2007）,a number that is extremely small compared to the total working population of approximately 63,000,000 workers（2007）.The ratio of accidents involving mariners（occupational accidents causing absences of more than four days）,however,is consistently higher when compared with occupational accidents on land（See Fig.1 and Fig.2）.

关键词： Safety and Health Mariner’s accident Mariners Law

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

International Journal of Oral Science 2018年第2期10卷 92-101页

作者： Kimito Hirai Hisako furusho Kiichi Hirota Hajime Sasaki Department of Cariology Restorative Sciences & Endodontics University of Michigan School of Dentistry Department of Immunology and Infectious Diseases The Forsyth Institute Department of Oral and Maxillofacial Pathobiology Hiroshima University Department of Human Stress Response Science Institute of Biomedical Science Kansai Medical University

Hypoxia（low oxygen level） is an important feature during infections and affects the host defence mechanisms. The host has evolved specific responses to address hypoxia, which are strongly dependent on the activation of hypoxia-inducible factor 1（HIF-1）.Hypoxia interferes degradation of HIF-1 alpha subunit（HIF-1α）, leading to stabilisation of HIF-1α, heterodimerization with HIF-1 beta subunit（HIF-1β） and subsequent activation of HIF-1 pathway. Apical periodontitis（periapical lesion） is a consequence of endodontic infection and ultimately results in destruction of tooth-supporting tissue, including alveolar bone. Thus far, the role of HIF-1 in periapical lesions has not been systematically examined. In the present study, we determined the role of HIF-1 in a wellcharacterised mouse periapical lesion model using two HIF-1α-activating strategies, dimethyloxalylglycine（DMOG） and adenovirusinduced constitutively active HIF-1α（CA-HIF1 A）. Both DMOG and CA-HIF1 A attenuated periapical inflammation and tissue destruction. The attenuation in vivo was associated with downregulation of nuclear factor-κappa B（NF-κB） and osteoclastic gene expressions. These two agents also suppressed NF-κB activation and subsequent production of proinflammatory cytokines by macrophages. Furthermore, activation of HIF-1α by DMOG specifically suppressed lipopolysaccharide-stimulated macrophage differentiation into M1 cells, increasing the ratio of M2 macrophages against M1 cells. Taken together, our data indicated that activation of HIF-1 plays a protective role in the development of apical periodontitis via downregulation of NF-κB, proinflammatory cytokines, M1 macrophages and osteoclastogenesis.

关键词： CA Activation hypoxia-inducible factor attenuates periapical inflammation bone loss HIF

Emerging therapeutic options in inflammatory bowel disease

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2021年第48期27卷 8242-8261页

作者： Jesus K Yamamoto-furusho Norma N Parra-Holguín Gastroenterology Unit Inflammatory Bowel Disease ClinicInstituto Nacional de Ciencias Medicas y NutricionMexico City 14080Mexico

Inflammatory bowel disease(IBD)is a chronic disease that requires chronic treatment throughout the evolution of the disease,with a complex physiopathology that entails great challenges for the development of new and specific treatments for ulcerative colitis and Crohn's *** anti-tumor necrosis factor alpha therapy has impacted the clinical course of IBD in those patients who do not respond to conventional treatment,so there is a need to develop new therapies and markers of treatment *** pathways involved in the development of the disease are known and the new therapies have focused on blocking the inflammatory process at the gastrointestinal level by oral,intravenous,subcutaneous,and topical *** these new therapies can lead to more personalized treatments with higher success rates and fewer *** treatments have not only focused on clinical remission,but also on achieving macroscopic changes at the endoscopic level and microscopic changes by achieving mucosal *** treatments are mainly based on modifying signaling pathways,by blocking receptors or ligands,reducing cell migration and maintaining the integrity of the epithelial ***,this review presents the efficacy and safety of the new treatments that are currently under study and the advances that have been made in this area in recent years.

关键词： Inflammatory bowel disease Review Emerging Treatment Ulcerative colitis Crohn's disease

Rheumatic manifestations of inflammatory bowel disease

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2009年第44期15卷 5517-5524页

作者： Tatiana Sofía Rodríguez-Reyna Cynthia Martínez-Reyes Jesús Kazúo Yamamoto-furusho Department of Immunology and Rheumatology National Institute of Medical Sciences and Nutrition Salvador ZubiránVasco de Quiroga 15Col Sección XVI. DelTlalpanMexico City 14000Mexico Department of Gastro-enterology National Institute of Medical Sciences and Nutrition Salvador ZubiránVasco de Quiroga 15Col Sección XVI. DelTlalpanMexico City 14000Mexico

This article reviews the literature concerning rheu-matic manifestations of inflammatory bowel disease (IBD),including common immune-mediated pathways,frequency,clinical course and therapy. Musculoskel-etal complications are frequent and well-recognized manifestations in IBD,and affect up to 33% of pa-tients with IBD. The strong link between the bowel and the osteo-articular system is suggested by many clinical and experimental observations,notably in HLA-B27 transgenic rats. The autoimmune pathogenic mechanisms shared by IBD and spondyloarthropathies include genetic susceptibility to abnormal antigen pre-sentation,aberrant recognition of self,the presence of autoantibodies against specific antigens shared by the colon and other extra-colonic tissues,and increased intestinal permeability. The response against microor-ganisms may have an important role through molecular mimicry and other mechanisms. Rheumatic mani-festations of IBD have been divided into peripheral arthritis,and axial involvement,including sacroiliitis,with or without spondylitis,similar to idiopathic anky-losing spondylitis. Other periarticular features can oc-cur,including enthesopathy,tendonitis,clubbing,peri-ostitis,and granulomatous lesions of joints and *** and osteomalacia secondary to IBD and iatrogenic complications can also occur. The manage-ment of the rheumatic manifestations of IBD consists of physical therapy in combination with local injection of corticosteroids and nonsteroidal anti-inflammatory drugs; caution is in order however,because of their possible harmful effects on intestinal integrity,perme-ability,and even on gut inflammation. Sulfasalazine,methotrexate,azathioprine,cyclosporine and lefluno-mide should be used for selected indications. In some cases,tumor necrosis factor-α blocking agents should be considered as first-line therapy.

关键词：风湿炎症肠

Genetic factors associated with the development of inflammatory bowel disease

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2007年第42期13卷 5594-5597页

作者： Jesus K Yamamoto-furusho Inflammatory Bowel DiseaseClinic Department of Gastroenterology Instituto Nacional deCiencias Médicas y Nutrición Vasco de Quiroga 15 ColoniaSección XVI Tlalpan C.P. 14000 México D.F. México

Crohn's disease(CD)and ulcerative colitis(UC)are complex polygenic disorders,characterized by several genes together with environmental factors contributing to the development of inflammatory bowel disease(IBD).Recent advances in research on genetic susceptibility have allowed the identification of diverse genes at different levels:(1)Innate immunity;(2)Antigen presentation molecules;(3)Epithelial integrity;(4)Drug transporter;(5)Cell *** application of genetic testing into clinical practice is close and all genetic markers may have several clinical implications:prediction of disease phenotype,molecular classification,prevention of complications,and prognosis.

关键词：肠炎克罗恩氏病遗传因子发病机理

Innovative therapeutics for inflammatory bowel disease

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2007年第13期13卷 1893-1896页

作者： Jesus K Yamamoto-furusho Inflammatory Bowel Diseas Clinic Department of Gastroenterology Instituto Nacional d Ciencias Médicas y Nutrición. Vasco de Quiroga 15 Coloni Sección XVI Tlalpan México CP 14000 DF México

Inflammatory bowel diseases (IBD) are chronic inflammatory conditions of the gastrointestinal tract, which clinically present as one of two disorders, Crohn's disease or ulcerative colitis. Mainstays of drug treatments for IBD include aminosalicylates, corticosteroids and immunosuppressants such as azathioprine, methotrexate and cyclosporin. Advances in basic research of the pathophysiological process in IBD have been applied to generate a variety of new therapeutics targeting at different levels of the inflammatory processes. New therapies are classified as: (1) Anti-TNFα antibodies; (2) Recombinant cytokines; (3) Selective adhesion blockade; (4) Growth factors; (5) Innate immunostimulation; (6) Nucleic acid based therapies; (7) Gene therapy; (8) Autologous bone-marrow transplantation; (9) Helminths and (10) Extracorporeal immunomodulation. All treatments have the potential to provide more effective and safe treatment for IBD.

关键词：炎症性肠病生物疗法创新疗法治疗新药

Innate immunity in inflammatory bowel disease

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2007年第42期13卷 5577-5580页

作者： Jesus K Yamamoto-furusho Daniel K Podolsky Gastrointestinal Unit and Center for the Study of Inflammatory BowelDisease Massachusetts General Hospital and Harvard MedicalSchool Boston MA 02114 United States

The human intestinal tract is home to an enormous bacterial *** host defense against microorganisms can be divided into innate and adaptive immunity The former is the most immediate line of response to immunologic challenges presented by bacteria viruses,and *** mucosal immune system has evolved to balance the need to respond to pathogens while co-existing with commensal bacteria and food *** inflammatory bowel disease(IBD),this hyporesponsiveness or tolerance breaks down and inflammation supervenes driven by the intestina microbial *** contain compounds and are recognized by a variety of receptors,including Toll-like receptors(TLRs)and NODs(a family of intracellula bacterial sensors)and are potent stimuli of innate immune *** mutations in these receptors have been associated with development of IBD.

关键词：肠炎发病机理先天免疫力胞内细菌受体

Crohn’s disease:Innate immunodeficiency?

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2006年第42期12卷 6751-6755页

作者： Jesus K Yamamoto-furusho Joshua R Korzenik Gastro-intestinal Unit and Center for the Study of Inflammatory Bowel Disease Massachusetts General Hospital and Harvard Medical School Boston MA 02114 United States

In the past, Crohn’s disease (CD) has been understood primarily as an immunologic disorder characterized by an abnormal T-cell response. Recent in vitro and in vivo data suggests that CD may instead be precipitated by innate immune dysfunction resulting from a combination of genetic and environmental factors. Some reports have demonstrated a defective immune response in a variety of other cellular components, including neutrophils, monocytes and dendritic cells. Recent studies of granulocyte-macrophage colony-stimulating factor (GM- CSF) in CD, aiming to stimulate the innate immune system with the conception that an innate immune defect underlies the development of the disease, have been demonstrated a clinical benefit and reinforce this evolving understanding of the disease.

关键词：结肠疾病免疫机制治疗临床